<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00030576</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000069178 (PHL-002)</org_study_id>
    <secondary_id>PMH-PHL-002</secondary_id>
    <secondary_id>NCI-5380</secondary_id>
    <secondary_id>CAN-NCIC-IND157</secondary_id>
    <nct_id>NCT00030576</nct_id>
  </id_info>
  <brief_title>Erlotinib and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer</brief_title>
  <official_title>A Phase I/II Study Of OSI-774 In Combination With Cisplatin In Patients With Recurrent Or Metastatic Squamous Cell Cancer Of The Head And Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies such as erlotinib may interfere with the growth of tumor&#xD;
      cells and slow the growth of the tumor. Drugs used in chemotherapy use different ways to stop&#xD;
      tumor cells from dividing so they stop growing or die. Combining erlotinib with cisplatin may&#xD;
      kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effectiveness of combining erlotinib and cisplatin in&#xD;
      treating patients who have recurrent or metastatic head and neck cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the objective response rate in patients with recurrent or metastatic squamous&#xD;
           cell cancer of the head and neck treated with erlotinib and cisplatin.&#xD;
&#xD;
        -  Determine the stable disease rates, duration of response, progression-free survival,&#xD;
           median survival, and overall survival of patients treated with this regimen.&#xD;
&#xD;
        -  Determine the safety and tolerability of this regimen in these patients.&#xD;
&#xD;
        -  Determine the relationship between clinical, pharmacokinetic, and pharmacodynamic&#xD;
           effects of this regimen in these patients.&#xD;
&#xD;
        -  Correlate baseline and post-treatment levels of epidermal growth factor receptor, its&#xD;
           downstream signaling components, and markers of angiogenesis and apoptosis in tumor and&#xD;
           skin biopsies with clinical outcome in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation, multicenter study.&#xD;
&#xD;
      Patients receive oral erlotinib once daily on days -6 to 21 for the first course only and&#xD;
      cisplatin IV over 60 minutes on day 1. For the second and subsequent courses, patients&#xD;
      receive oral erlotinib once daily on days 1-21 and cisplatin as in course 1. Treatment&#xD;
      repeats every 21 days for up to 6 courses in the absence of disease progression or&#xD;
      unacceptable toxicity. Patients with stable or responding disease after 6 courses may&#xD;
      continue to receive erlotinib alone until disease progression.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of erlotinib and cisplatin until the maximum&#xD;
      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2&#xD;
      of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at&#xD;
      the MTD.&#xD;
&#xD;
      Patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 43 patients will be accrued for this study within 18 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2001</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>OSI-774 and cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HNSCC patients treated in three escalating dose cohorts of daily continous oral erlotinib (OSI-774) and intermittent IV cisplatin given every 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <arm_group_label>OSI-774 and cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib hydrochloride</intervention_name>
    <arm_group_label>OSI-774 and cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed squamous cell carcinoma of the head and neck&#xD;
&#xD;
               -  All primary sites, including oral cavity, oropharynx, nasopharynx, hypopharynx,&#xD;
                  larynx, and paranasal sinus&#xD;
&#xD;
          -  Recurrent, unresectable, and/or metastatic disease&#xD;
&#xD;
          -  At least 1 measurable lesion&#xD;
&#xD;
               -  At least 20 mm with conventional techniques OR at least 10 mm with spiral CT scan&#xD;
&#xD;
          -  Lesions accessible for biopsy&#xD;
&#xD;
          -  Tumor specimen available for evaluation of epidermal growth factor receptor (EGFR)&#xD;
             expression&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2 OR&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 12 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.25 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT no greater than 2.5 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine normal OR&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
        Gastrointestinal:&#xD;
&#xD;
          -  No gastrointestinal tract disease resulting in malabsorption&#xD;
&#xD;
          -  No requirement for IV alimentation&#xD;
&#xD;
          -  No active peptic ulcer disease&#xD;
&#xD;
          -  Inability to swallow tablets or silicon-based G-tubes allowed&#xD;
&#xD;
        Ophthalmic:&#xD;
&#xD;
          -  No abnormalities of the cornea based on history (e.g., dry eye syndrome or Sjogren's&#xD;
             syndrome)&#xD;
&#xD;
          -  No congenital abnormality (e.g., Fuch's dystrophy)&#xD;
&#xD;
          -  No abnormal slit-lamp examination using a vital dye (e.g., fluorescein or Bengal-Rose)&#xD;
&#xD;
          -  No abnormal corneal sensitivity test (e.g., Schirmer test or similar tear production&#xD;
             test)&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other malignancy within the past 5 years except carcinoma in situ of the cervix,&#xD;
             nonmelanoma skin cancer, or second primary squamous cell cancer originating from the&#xD;
             head and neck&#xD;
&#xD;
          -  No grade 2 or greater residual ototoxicity or neuropathy from prior platinum-based&#xD;
             therapy&#xD;
&#xD;
          -  No significant traumatic injury within the past 21 days&#xD;
&#xD;
          -  No other concurrent uncontrolled illness&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior chemotherapy for recurrent or metastatic disease&#xD;
&#xD;
          -  Prior platinum-based chemotherapy with radiotherapy or platinum-based induction&#xD;
             chemotherapy allowed&#xD;
&#xD;
          -  At least 6 months since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Chemotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy (except low-dose, limited-fraction&#xD;
             palliative non-myelosuppressive radiotherapy [e.g., involving less than 20% of&#xD;
             functioning bone marrow using 800 cGy in 1 fraction or 2,000 cGy in 5 fractions]) and&#xD;
             recovered&#xD;
&#xD;
          -  No prior radiotherapy to target lesion unless there is evidence of disease progression&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 21 days since prior major surgery&#xD;
&#xD;
          -  No prior surgical procedure affecting gastrointestinal absorption&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No prior EGFR-targeting therapies&#xD;
&#xD;
          -  No prior investigational agents for recurrent or metastatic disease&#xD;
&#xD;
          -  No concurrent combination anti-retroviral therapy for HIV infection&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent anticancer treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lillian L. Siu, MD, FRCPC</last_name>
    <role>Study Chair</role>
    <affiliation>Princess Margaret Hospital, Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elizabeth A. Eisenhauer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cancer Research Institute at Queen's University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Margaret and Charles Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen's University</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 3N6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Ontario-London Regional Cancer Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Regional Cancer Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Universite de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L-4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Agulnik M, da Cunha Santos G, Hedley D, Nicklee T, Dos Reis PP, Ho J, Pond GR, Chen H, Chen S, Shyr Y, Winquist E, Soulieres D, Chen EX, Squire JA, Marrano P, Kamel-Reid S, Dancey J, Siu LL, Tsao MS. Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. J Clin Oncol. 2007 Jun 1;25(16):2184-90.</citation>
    <PMID>17538163</PMID>
  </results_reference>
  <results_reference>
    <citation>Siu LL, Soulieres D, Chen EX, Pond GR, Chin SF, Francis P, Harvey L, Klein M, Zhang W, Dancey J, Eisenhauer EA, Winquist E; Princess Margaret Hospital Phase II Consortium; National Cancer Institute of Canada Clinical Trials Group Study. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol. 2007 Jun 1;25(16):2178-83.</citation>
    <PMID>17538162</PMID>
  </results_reference>
  <results_reference>
    <citation>Winquist E, Soulieres D, Chen E, et al.: A phase II study of erlotinib in combination with cisplatin in patients with recurrent or metastatic squamous cell cancer of the head and neck (PHL002es/NCIC CTG IND.157). [Abstract] Eur J Cancer 2 (Suppl 8): A-408, 122, 2004.</citation>
  </results_reference>
  <results_reference>
    <citation>Siu LL, Chen X, Tsao M: A phase I/II study of erlotinib (Tarceva) in combination with cisplatin in patients with recurrent or metastatic squamous cell cancer of the head and neck (HNSCC). [Abstract] Clin Cancer Res 9 (16): A-A92, 2003.</citation>
  </results_reference>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>February 14, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>October 9, 2018</last_update_submitted>
  <last_update_submitted_qc>October 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent metastatic squamous neck cancer occult primary</keyword>
  <keyword>neck cancer with occult primary squamous carcinoma</keyword>
  <keyword>stage IV squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the oropharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the larynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the larynx</keyword>
  <keyword>squamous cell carcinoma of paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of sinus and nasal cavity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>May 8, 2019</submitted>
    <returned>May 28, 2019</returned>
    <submitted>September 9, 2020</submitted>
    <returned>October 2, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

